文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛心脑血管急症

急性呼吸窘迫综合征中脑损伤与神经结局的病理生理:从临床前到临床研究的范围综述

Pathophysiology of Brain Injury and Neurological Outcome in Acute Respiratory Distress Syndrome: A Scoping Review of Preclinical to Clinical Studies.
PubMed 文献 · Neurocrit Care · 2021-07-23
一句话结论ARDS相关继发性脑损伤常见,临床观察中不良神经结局达82-86%,出院时认知障碍87%,需关注脑保护。

本范围综述系统检索PubMed等6个数据库至2020年7月6日,纳入38项研究(10项临床前研究143只动物;28项临床研究1175例患者)。动物研究显示海马神经炎症和神经元损伤、肺保护性机械通气下脑血流改变和颅内压升高。临床观察研究中ARDS相关继发性脑损伤或不良神经结局发生率为82-86%;最常见为出血性卒中(25%),其次缺氧缺血性脑损伤(22%)、弥漫性脑水肿(11%)、缺血性卒中(8%)。ARDS患者出院时认知障碍87%,6个月36%,1年30%。机制包括原发缺氧缺血性损伤、肺损伤诱导的神经炎症和肺保护性通气策略相关的颅内压升高。

要点

  • 临床观察研究中ARDS相关继发性脑损伤或不良神经结局发生率高达82-86%。
  • ARDS患者出院时认知障碍发生率为87%(范围73-100%),6个月降至36%(32-37%),1年30%(25-45%)。
  • 临床报告的继发性脑损伤中出血性卒中占25%,缺氧缺血性脑损伤占22%。
  • 动物研究提示肺保护性机械通气可改变脑血流并升高颅内压。
  • ARDS相关脑损伤机制包括缺氧缺血性损伤、神经炎症和颅内压升高。

适用人群与场景

  • 纳入报告ARDS后发生继发性急性脑损伤(ABI)或神经结局的研究;临床研究共1175例患者,临床报告的ABI患者中位年龄49岁,46%为男性。
  • 动物研究共143只动物;临床前研究关注ARDS模型中的脑损伤机制。
  • 原文未明确排除人群及具体急诊/ICU场景。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • ARDS患者出现继发性脑损伤,常见类型包括出血性卒中(25%)、缺氧缺血性脑损伤(22%)、弥漫性脑水肿(11%)、缺血性卒中(8%)。
  • ARDS患者出院时认知障碍发生率高达87%,需关注长期神经认知功能。

研究设计与关键结果

  • 研究类型:范围综述,系统检索PubMed等6个数据库至2020年7月6日,纳入38项研究(10项临床前研究143只动物;28项临床研究1175例患者)。
  • 动物研究:6项显示海马神经炎症和神经元损伤证据;5项显示肺保护性机械通气下脑血流改变和颅内压升高。
  • 临床观察研究:ARDS相关继发性ABI或不良神经结局发生率为82-86%。
  • 临床报告的ABI类型:出血性卒中25%,缺氧缺血性脑损伤22%,弥漫性脑水肿11%,缺血性卒中8%。
  • 认知障碍:ARDS患者(n=797)出院时87%(范围73-100%),6个月36%(范围32-37%),1年30%(范围25-45%)。

证据类型、等级与局限

  • 证据类型:范围综述,汇总临床前和临床研究。
  • 局限:原文指出关于ARDS患者ABI患病率的临床数据匮乏;未提供证据等级或推荐强度。

对床旁实践的改变

  • 原文提示ARDS患者应关注继发性脑损伤和长期认知障碍,但未提供具体实践改变建议。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Acute respiratory distress syndrome (ARDS) has been associated with secondary acute brain injury (ABI). However, there is sparse literature on the mechanism of lung-mediated brain injury and prevalence of ARDS-associated secondary ABI. We aimed to review and elucidate potential mechanisms of ARDS-mediated ABI from preclinical models and assess the prevalence of ABI and neurological outcome in ARDS with clinical studies. We conducted a systematic search of PubMed and five other databases reporting ABI and ARDS through July 6, 2020 and included studies with ABI and neurological outcome occurring after ARDS. We found 38 studies (10 preclinical studies with 143 animals; 28 clinical studies with 1175 patients) encompassing 9 animal studies (n = 143), 1 in vitro study, 12 studies on neurocognitive outcomes (n = 797), 2 clinical observational studies (n = 126), 1 neuroimaging study (n = 15), and 13 clinical case series/reports (n = 15). Six ARDS animal studies demonstrated evidence of neuroinflammation and neuronal damage within the hippocampus. Five animal studies demonstrated altered cerebral blood flow and increased intracranial pressure with the use of lung-protective mechanical ventilation. High frequency of ARDS-associated secondary ABI or poor neurological outcome was observed ranging 82-86% in clinical observational studies. Of the clinically reported ABIs (median age 49 years, 46% men), the most common injury was hemorrhagic stroke (25%), followed by hypoxic ischemic brain injury (22%), diffuse cerebral edema (11%), and ischemic stroke (8%). Cognitive impairment in patients with ARDS (n = 797) was observed in 87% (range 73-100%) at discharge, 36% (range 32-37%) at 6 months, and 30% (range 25-45%) at 1 year. Mechanisms of ARDS-associated secondary ABI include primary hypoxic ischemic injury from hypoxic respiratory failure, secondary injury, such as lung injury induced neuroinflammation, and increased intracranial pressure from ARDS lung-protective mechanical ventilation strategy. In summary, paucity of clinical data exists on the prevalence of ABI in patients with ARDS. Hemorrhagic stroke and hypoxic ischemic brain injury were commonly observed. Persistent cognitive impairment was highly prevalent in patients with ARDS.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Huang M, Gedansky A, Hassett CE, et al. Pathophysiology of Brain Injury and Neurological Outcome in Acute Respiratory Distress Syndrome: A Scoping Review of Preclinical to Clinical Studies. Neurocrit Care. 2021. PMID: 34297332. doi:10.1007/s12028-021-01309-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。